Amenamevir: Studies of Potential CYP3A‐Mediated Pharmacokinetic Interactions With Midazolam, Cyclosporine, and Ritonavir in Healthy Volunteers

Amenamevir (formerly ASP2151) is a helicase‐primase inhibitor being developed for the treatment of herpesvirus infection. Amenamevir is both a substrate and inducer of cytochrome P450 (CYP) 3A4. Three studies were done in healthy volunteers to investigate potential CYP3A pharmacokinetic interactions...

Descripción completa

Detalles Bibliográficos
Autores principales: Adeloye, Temitope, Sahgal, Omair, Puri, Adeep, Warrington, Steve, Endo, Takamasa, Dennison, Jeremy, Johnston, Atholl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585933/
https://www.ncbi.nlm.nih.gov/pubmed/30044899
http://dx.doi.org/10.1002/cpdd.586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585933/
https://www.ncbi.nlm.nih.gov/pubmed/30044899
http://dx.doi.org/10.1002/cpdd.586

Ejemplares similares